Merck Animal Health completes acquisition of Elanco’s aqua business

The Merck campus in Rahway and Linden.

Merck Animal Health on Tuesday said it completed the previously announced acquisition of the aqua business of Elanco Animal Health Inc. The completion of this acquisition bolsters Merck Animal Health’s position in the aqua industry with a comprehensive approach to promote fish health, welfare and sustainability in aquaculture, conservation and fisheries.

“With the completion of this acquisition, we are well-positioned within the aquaculture industry with a robust and comprehensive portfolio across warm water, cold water, vaccines, anti-parasitic treatments, water supplements and nutrition,” Rick DeLuca, president, Merck Animal Health, said. “We are excited to welcome our new colleagues to Merck Animal Health and we look forward to working together, driven by our common purpose of the Science of Healthier Animals.”

As a result of the acquisition, Rahway-based Merck Animal Health now owns innovative products such as a new-generation DNA-based vaccine that protects Atlantic salmon against pancreas disease.

The increasing use of medicines and vaccines, nutritionals and supplements for aquatic species is driven by the growing demand for protein and food safety, ensuring a supply of quality food and protecting public health.